{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T11:32:12Z","timestamp":1788089532958,"version":"build-2803163510"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,19]]},"DOI":"10.7759\/cureus.99657","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T23:33:57Z","timestamp":1766187237000},"source":"Crossref","is-referenced-by-count":1,"title":["Effective Use of Olanzapine for Chemotherapy-Induced Nausea and Vomiting in a Patient Receiving Dose-Adjusted Rituximab, Etoposide, Prednisone, Vincristine (Oncovin\u00ae), Cyclophosphamide, and Doxorubicin (R-EPOCH): A Case Report"],"prefix":"10.7759","author":[{"given":"Hirokazu","family":"Shimada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Ohgami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasumitsu","family":"Kurokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeki","family":"Tachihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinori","family":"Sugaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-006-0173-z","article-title":"Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings","volume":"15","author":"Cohen L","year":"2007","unstructured":"Cohen L, de Moor CA, Eisenberg P, Ming EE, Hu H. Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings. Support Care Cancer. 2007, 15:497-503. 10.1007\/s00520-006-0173-z","journal-title":"Support Care Cancer"},{"key":"ref2","unstructured":"CTCAE and adverse event reporting. (2017). Accessed. November 14, 2025: https:\/\/dctd.cancer.gov\/research\/ctep-trials\/for-sites\/adverse-events."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-019-04778-1","article-title":"Prognostic role of chemotherapy-induced nausea and vomiting in recurrent ovarian cancer patients: results of an individual participant data meta-analysis in 1213","volume":"28","author":"Woopen H","year":"2020","unstructured":"Woopen H, Richter R, Chekerov R, Inci G, Alavi S, Grabowski JP, Sehouli J. Prognostic role of chemotherapy-induced nausea and vomiting in recurrent ovarian cancer patients: results of an individual participant data meta-analysis in 1213. Support Care Cancer. 2020, 28:73-8. 10.1007\/s00520-019-04778-1","journal-title":"Support Care Cancer"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1515725","article-title":"Olanzapine for the prevention of chemotherapy-induced nausea and vomiting","volume":"375","author":"Navari RM","year":"2016","unstructured":"Navari RM, Qin R, Ruddy KJ, et al.. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. N Engl J Med. 2016, 375:134-42. 10.1056\/NEJMoa1515725","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/0893-133X(94)00129-N","article-title":"Radioreceptor binding profile of the atypical antipsychotic olanzapine","volume":"14","author":"Bymaster FP","year":"1996","unstructured":"Bymaster FP, Calligaro DO, Falcone JF, et al.. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology. 1996, 14:87-96. 10.1016\/0893-133X(94)00129-N","journal-title":"Neuropsychopharmacology"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01296","article-title":"Antiemetics: ASCO guideline update","volume":"38","author":"Hesketh PJ","year":"2020","unstructured":"Hesketh PJ, Kris MG, Basch E, et al.. Antiemetics: ASCO guideline update. J Clin Oncol. 2020, 38:2782-97. 10.1200\/JCO.20.01296","journal-title":"J Clin Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.102195","article-title":"2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting","volume":"9","author":"Herrstedt J","year":"2024","unstructured":"Herrstedt J, Clark-Snow R, Ruhlmann CH, et al.. 2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting. ESMO Open. 2024, 9:102195. 10.1016\/j.esmoop.2023.102195","journal-title":"ESMO Open"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2020.11.002","article-title":"A randomized trial of individualized versus standard of care antiemetic therapy for breast cancer patients at high risk for chemotherapy-induced nausea and vomiting","volume":"54","author":"Clemons M","year":"2020","unstructured":"Clemons M, Dranitsaris G, Sienkiewicz M, et al.. A randomized trial of individualized versus standard of care antiemetic therapy for breast cancer patients at high risk for chemotherapy-induced nausea and vomiting. Breast. 2020, 54:278-85. 10.1016\/j.breast.2020.11.002","journal-title":"Breast"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v99.8.2685","article-title":"Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy","volume":"99","author":"Wilson WH","year":"2002","unstructured":"Wilson WH, Grossbard ML, Pittaluga S, et al.. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood. 2002, 99:2685-93. 10.1182\/blood.v99.8.2685","journal-title":"Blood"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1177\/1078155220967722","article-title":"Antiemetic medication efficacy during EPOCH and R-EPOCH treatment","volume":"27","author":"Fleming MK","year":"2021","unstructured":"Fleming MK, Carr A, Li J, Lundberg JD, Rogers KA. Antiemetic medication efficacy during EPOCH and R-EPOCH treatment. J Oncol Pharm Pract. 2021, 27:1691-8. 10.1177\/1078155220967722","journal-title":"J Oncol Pharm Pract"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1177\/1078155220985919","article-title":"Evaluating the incidence of chemotherapy-induced nausea and vomiting in patients with B-cell lymphoma receiving dose-adjusted EPOCH and rituximab","volume":"28","author":"Uchida E","year":"2022","unstructured":"Uchida E, Lei MM, Roeland E, Lou U. Evaluating the incidence of chemotherapy-induced nausea and vomiting in patients with B-cell lymphoma receiving dose-adjusted EPOCH and rituximab. J Oncol Pharm Pract. 2022, 28:119-26. 10.1177\/1078155220985919","journal-title":"J Oncol Pharm Pract"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1177\/10781552241312097","article-title":"Addition of an NK1 receptor antagonist to standard antiemetic prophylaxis in patients with B-cell lymphoma receiving EPOCH","author":"English S","year":"2025","unstructured":"English S, Lei M, Sorial M, Roeland EJ, Lou U. Addition of an NK1 receptor antagonist to standard antiemetic prophylaxis in patients with B-cell lymphoma receiving EPOCH. J Oncol Pharm Pract. 2025, 10781552241312097. 10.1177\/10781552241312097","journal-title":"J Oncol Pharm Pract"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101771","article-title":"A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial of olanzapine plus triple antiemetic regimen for the prevention of multiday highly emetogenic chemotherapy-induced nausea and vomiting (OFFER study)","volume":"55","author":"Zhao Y","year":"2023","unstructured":"Zhao Y, Yang Y, Gao F, et al.. A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial of olanzapine plus triple antiemetic regimen for the prevention of multiday highly emetogenic chemotherapy-induced nausea and vomiting (OFFER study). EClinicalMedicine. 2023, 55:101771. 10.1016\/j.eclinm.2022.101771","journal-title":"EClinicalMedicine"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214561","article-title":"Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma","volume":"368","author":"Dunleavy K","year":"2013","unstructured":"Dunleavy K, Pittaluga S, Maeda LS, et al.. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med. 2013, 368:1408-16. 10.1056\/NEJMoa1214561","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.06.005","article-title":"Randomized, placebo-controlled, phase III trial of fosaprepitant, ondansetron, dexamethasone (FOND) versus fond plus olanzapine (FOND-O) for the prevention of chemotherapy-induced nausea and vomiting in patients with hematologic malignancies receiving highly emetogenic chemotherapy and hematopoietic cell transplantation regimens: the FOND-O trial","volume":"24","author":"Clemmons AB","year":"2018","unstructured":"Clemmons AB, Orr J, Andrick B, Gandhi A, Sportes C, DeRemer D. Randomized, placebo-controlled, phase III trial of fosaprepitant, ondansetron, dexamethasone (FOND) versus fond plus olanzapine (FOND-O) for the prevention of chemotherapy-induced nausea and vomiting in patients with hematologic malignancies receiving highly emetogenic chemotherapy and hematopoietic cell transplantation regimens: the FOND-O trial. Biol Blood Marrow Transplant. 2018, 24:2065-71. 10.1016\/j.bbmt.2018.06.005","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1186\/1710-1492-9-30","article-title":"A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy","volume":"9","author":"Liu D","year":"2013","unstructured":"Liu D, Ahmet A, Ward L, et al.. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol. 2013, 9:30. 10.1186\/1710-1492-9-30","journal-title":"Allergy Asthma Clin Immunol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30678-3","article-title":"Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"21","author":"Hashimoto H","year":"2020","unstructured":"Hashimoto H, Abe M, Tokuyama O, et al.. Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020, 21:242-9. 10.1016\/S1470-2045(19)30678-3","journal-title":"Lancet Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S68130","article-title":"Update on the management of chemotherapy-induced nausea and vomiting - focus on palonosetron","volume":"11","author":"Zhou M","year":"2015","unstructured":"Zhou M, Popovic M, Pasetka M, Pulenzas N, Ahrari S, Chow E, DeAngelis C. Update on the management of chemotherapy-induced nausea and vomiting - focus on palonosetron. Ther Clin Risk Manag. 2015, 11:713-29. 10.2147\/TCRM.S68130","journal-title":"Ther Clin Risk Manag"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00628-9","article-title":"Low-dose versus standard-dose olanzapine with triple antiemetic therapy for prevention of highly emetogenic chemotherapy-induced nausea and vomiting in patients with solid tumours: a single-centre, open-label, non-inferiority, randomised, controlled, phase 3 trial","volume":"25","author":"Bajpai J","year":"2024","unstructured":"Bajpai J, Kapu V, Rath S, et al.. Low-dose versus standard-dose olanzapine with triple antiemetic therapy for prevention of highly emetogenic chemotherapy-induced nausea and vomiting in patients with solid tumours: a single-centre, open-label, non-inferiority, randomised, controlled, phase 3 trial. Lancet Oncol. 2024, 25:246-54. 10.1016\/S1470-2045(23)00628-9","journal-title":"Lancet Oncol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejon.2024.102540","article-title":"Acute, long-term or non-vincristine-induced peripheral neuropathy among non-Hodgkin lymphoma survivors: Symptoms, daily activities, functional status, and quality of life","volume":"69","author":"Su YC","year":"2024","unstructured":"Su YC, Lai YH, Hsieh ST, Teng CJ, Lee YH. Acute, long-term or non-vincristine-induced peripheral neuropathy among non-Hodgkin lymphoma survivors: Symptoms, daily activities, functional status, and quality of life. Eur J Oncol Nurs. 2024, 69:102540. 10.1016\/j.ejon.2024.102540","journal-title":"Eur J Oncol Nurs"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2012.06.010","article-title":"In vitro and in vivo pharmacological characterization of the novel NK\u2081 receptor selective antagonist netupitant","volume":"37","author":"Rizzi A","year":"2012","unstructured":"Rizzi A, Campi B, Camarda V, et al.. In vitro and in vivo pharmacological characterization of the novel NK\u2081 receptor selective antagonist netupitant. Peptides. 2012, 37:86-97. 10.1016\/j.peptides.2012.06.010","journal-title":"Peptides"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01315","article-title":"Randomized, double-blind, phase III study of fosnetupitant versus fosaprepitant for prevention of highly emetogenic chemotherapy-induced nausea and vomiting: CONSOLE","volume":"40","author":"Hata A","year":"2022","unstructured":"Hata A, Okamoto I, Inui N, et al.. Randomized, double-blind, phase III study of fosnetupitant versus fosaprepitant for prevention of highly emetogenic chemotherapy-induced nausea and vomiting: CONSOLE. J Clin Oncol. 2022, 40:180-8. 10.1200\/JCO.21.01315","journal-title":"J Clin Oncol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34088","article-title":"A phase 3 safety study of fosnetupitant as an antiemetic in patients receiving anthracycline and cyclophosphamide: CONSOLE-BC","volume":"128","author":"Matsuura K","year":"2022","unstructured":"Matsuura K, Tsurutani J, Inoue K, et al.. A phase 3 safety study of fosnetupitant as an antiemetic in patients receiving anthracycline and cyclophosphamide: CONSOLE-BC. Cancer. 2022, 128:1692-8. 10.1002\/cncr.34088","journal-title":"Cancer"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/424959-effective-use-of-olanzapine-for-chemotherapy-induced-nausea-and-vomiting-in-a-patient-receiving-dose-adjusted-rituximab-etoposide-prednisone-vincristine-oncovin-cyclophosphamide-and-doxorubicin-r-epoch-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T23:34:03Z","timestamp":1766187243000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/424959-effective-use-of-olanzapine-for-chemotherapy-induced-nausea-and-vomiting-in-a-patient-receiving-dose-adjusted-rituximab-etoposide-prednisone-vincristine-oncovin-cyclophosphamide-and-doxorubicin-r-epoch-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,19]]},"references-count":23,"URL":"https:\/\/doi.org\/10.7759\/cureus.99657","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,19]]}}}